Healthcare
Xeris Biopharma Holdings, Inc.(XERS)
Live Price
Offline$6.95
+0.72% today
1Y Change
+49.78%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $1.09B
- Revenue Growth
- +43.7%
- EPS Growth
- +100.9%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xeris Biopharma Holdings, Inc. (XERS) is a Healthcare stock with a market cap of $1.09B and listed on NASDAQ. The stock last traded around $6.95 and up 49.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +43.7%, EPS growth of +100.9%, a dividend yield of 0.0%. What stands out right now is revenue +43.7%, EPS +100.9%, free cash flow +173.8% with operating margin 8.5% and ROIC 8.9%. Valuation already assumes a fairly strong business story at P/E 1899.3 and price/sales 3.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XERS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+43.7% vs +7.6% peer median
Operating Margin
Below sector median
+8.5% vs +19.4% peer median
P/E
Above sector median
1899.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 7, 2026 with an EPS surprise of +465.0% and a revenue surprise of +3.3%.
The operating story is still moving forward
Revenue is running at +43.7% and EPS at +100.9%, with operating margin around 8.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | +465.0% | -1.5% | -3.8% | -6.8% |
2026 Mar 2, 2026 | +100.0% | -1.3% | -7.0% | -7.0% |
2025 Nov 6, 2025 | -65.0% | -3.6% | -5.8% | -15.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XERS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
XERS Max Drawdown
-46.57%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XERS and SPY.
Company Overview
Xeris Biopharma Holdings, Inc.
NASDAQ Global Select
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Leadership
- John Shannon
- IPO Date
- Jun 21, 2018
- Employees
- 394
- Street Address
- 180 North LaSalle Street
- Mailing
- Chicago, IL, 60601
- Region
- Chicago, IL, US
- Reporting Currency
- USD
- Investor Line
- 844 445 5704
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 1899.3
- EV/EBITDA
- 29.1
- Price/Sales
- 3.7
- Price/Book
- 76.9
Growth
- Revenue
- +43.7%
- EPS
- +100.9%
- Free Cash Flow
- +173.8%
Profitability
- Gross Margin
- 81.7%
- Operating Margin
- 8.5%
- Net Margin
- 0.2%
- ROE
- -5.3%
- ROIC
- 8.9%
Balance Sheet
- Debt/Equity
- 2.76
- Current Ratio
- 2.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.